Background/Aim. The main cause for development of endometrial hyperplasia represents
Introduction
Different types of morphological and physiological endometrial cell disorders may lead to development of endometrial diseases. One of them is presented in a form of endometrial hyperplasia. Uterine cells changes morfologicaly and physiologicaly during endometrial hyperplasia. These changes are represented as excessive glandular and stromal endometrial cells proliferation associated with different degrees of cellular atypia and morphological abnormalities 1, 2 . These changes include cystic dilatation of endometrial glands without secretion, anovulatory cycles and presence of abnormal bleeding 3 . As a 5 result of ongoing cell changes during endometrial hyperplasia, endometrium switches from normal towards tumorous tissue 2 . In women under the age of 30, endometrial hyperplasia is rare, however in age group of 50-54 years, an is increasing incidence has been recorded.
During aging, incidence of atypical endometrial hyperplasia with cytological changes increases as a prelude to a precancerous condition 4 . Treatment of endometrial hyperplasia is restricted to two types of approache. First treatment type is represented in a form of progestin (hormone) therapy, while second type of treatment is represented in surgical approach (hysterectomy) 5 . Progestin therapy approach is oriented towards one of the main problems leading to the development of endometrial hyperplasia -lack of progesterone component; while operative approach constitutes the last used technique considering complete removal of uterus and ovary. Mifepristone (RU-486, RU-38486) belongs to the class of progesterone and glucocorticoid receptor antagonist 6, 7 . This drug has various applications in different types of diseases. It has been showed that mifepristone can be suitable for patients with hyperglycemia as a secondary disorder in the Cushing's syndrome 8 , it induces miscarriage and it is used to oppose proliferative effect of estrogen on endometrium, treatment of endometriosis, leiomyoma, breast cancer, and meningioma 9, 10 .
Application of low doses of mifepristone express antiproliferative effects in various cancer of reproductive and non-reproductive organs 7, 9, 11, 12 . These data were confirmed in in vitro study performed by Goyenche et al. 13 . In this study Mifepristone exhibited inhibitory effect on ovarian cancer cell (SK-OV-3, Caov-3, OV2008, and IGROV-1) growth in vitro.
In research that was conducted by Almin et al., 10 it was shown that mifepristone induced apoptosis in Ishikawa cell lines through Bax translocation and caspase 3 activation;
Schneider et al., also confirmed role of mifepristone on apoptosis induction in endometrial 6 cancer cell lines (Hec-1A, KLE, and RL95-2) that involved changes in Bax and Bcl-2 regulation 11 .
The aim of our study was to investigate effects of single application of mifepristone on induction of apoptosis using human endometrial stromal cell line (ThESC cell line).
Methods

Cell line
In our study we have used human endometrial stromal cell line (ThESC cell line - 
MTT assay
Using a viability assay (MTT assay) cytotoxic effects of mifepristone was 
Apoptosis detection -flow cytometry
Type of cell death induced with investigated substances was determined with 
Immunofluorescence assay
Following the determination of cytotoxic effect of investigated drugs, in our next experiment we treated the cells with the lowest cytotoxic doses of investigated substances.
In order evaluate both the expression level and localization of two key members of Bcl-2 protein family, with pro-and anti-apoptotic activity 14 version. These values of fluorescence intensity obtained using ImageJ were transferred to
Excel and used to produce bar charts that represented the intensity of fluorescence for specific antibodies which are used in this experiments.
Statistical analysis
All values were expressed as mean ± standard deviation (SD). Each experiment was performed in triplicate and conducted on every sample as described earlier. Commercial SPSS version 24.0 was used for statistical analysis. Statistical evaluation was performed using Student's t-test for paired observations, or one-way ANOVA depending on data distribution. P values that were less than 0.05 (p≤0.05) were considered as significant. 
Results
Discussion
The benign changes in uterus that arise as the effect of prolonged and unopposed estrogen stimulation are dangerous for several reasons. First of all, extremely proliferated endometrial tissue derived as a result of estrogen effect on endometrium, can not be adequately nourished by blood vessels, ultimately resulting in endometrial shedding followed by prolonged and irregular discharge that is not relevant to menstrual cycle 15 .
Second 
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